Pfizer and Glenmark Pharmaceuticals Ltd announced a partnership on Wednesday to launch abrocitinib in India to treat moderate-to-severe atopic dermatitis. Known under the brand names JABRYUS and CIBINQO in India, marketed by Glenmark and Pfizer respectively, this novel oral medication has received approval from major regulatory bodies including the FDA and EMA.

Abrocitinib, also called CIBINQO, is designed to provide rapid relief from itching and long-term control of the disease for those suffering from this chronic skin condition, which is marked by inflammation and compromised skin barriers. The collaboration aims to bring this advanced treatment solution to the Indian market, leveraging the combined expertise and capabilities of Pfizer and Glenmark.

Meenakshi Nevatia, Country President and Managing Director of Pfizer India, emphasised the partnership’s role in utilising the strengths of both organisations to distribute this innovative therapy nationwide.

Already available in over 35 countries, including the USA, Japan, and China, abrocitinib’s introduction in India is timely, addressing a growing need in a country where around 5.9% of adults suffer from atopic dermatitis, with 4.4% experiencing severe forms. The condition’s symptoms, including itching and sleep disruption, significantly affect patients’ and caregivers’ quality of life and mental well-being.

Also Read | GenAI set to transform Asia/Pacific healthcare with $100 billion savings and 60% AI adoption by 2026 

Highlighting the rising prevalence of atopic dermatitis in India, attributed to environmental changes and often beginning in early life, Alok Malik, President and Business Head of India Formulations at Glenmark Pharmaceuticals Ltd, stated that this partnership strengthens their position in dermatology and ensures the availability of this effective treatment for Indian patients with moderate-to-severe atopic dermatitis.